Filing Analysis
Vivos Therapeutics received a deficiency notice from Nasdaq on April 17, 2026, for failing to maintain the minimum stockholders' equity requirement of $2.5 million. The company reported a negative stockholders' equity of approximately $1.55 million as of December 31, 2025.
Red Flags
- Negative stockholders' equity of $1.55 million.
- Receipt of a formal Nasdaq delisting notice.
- Heavy reliance on dilutive equity financing to maintain listing requirements.
Key Facts
- Nasdaq notice received on April 17, 2026, regarding Rule 5550(b)(1) non-compliance.
- Stockholders' equity was negative $1.55 million as of December 31, 2025.
- Company raised $6.8 million in gross proceeds during Q1 2026 through a $4.6 million warrant inducement and a $2.25 million private placement.
- The company has 45 days (until June 1, 2026) to submit a plan to regain compliance.
- If the plan is accepted, Nasdaq may grant an extension until October 14, 2026.
Vivos Therapeutics, Inc. issued a press release on April 15, 2026, announcing its financial results for the fiscal year ended December 31, 2025. The filing serves as a routine disclosure of the company's annual financial performance.
Key Facts
- The report was filed on April 15, 2026, regarding the fiscal year ended December 31, 2025.
- The company furnished a press release as Exhibit 99.1 under Item 2.02.
- The filing was signed by Bradford Amman, Chief Financial Officer.
Vivos Therapeutics entered into a $2.25 million PIPE offering with V-Co Investors 3 LLC, consisting of $850,000 in new cash and the conversion of a $1.4 million bridge note. The transaction is highly dilutive, involving the issuance of common stock, pre-funded warrants, and two series of common stock purchase warrants.
Red Flags
- Significant dilution: The total warrant coverage (including pre-funded) represents over 3.9 million shares against only 1.35 million common shares sold.
- Bridge note conversion: The conversion of a debt instrument issued only months prior (January 2026) suggests immediate liquidity needs.
- High cost of capital: The converted bridge note carried a $140,000 original issue discount (OID).
- Investor fee reimbursement: The company paid $50,000 for the investor's counsel, which is a high friction cost for an $850,000 cash raise.
Key Facts
- The PIPE offering closed on March 31, 2026, with V-Co Investors 3 LLC, an affiliate of New Seneca Partners Inc.
- The company sold 1,353,625 shares of common stock and a pre-funded warrant for 429,957 shares at a price of $1.34 per unit.
- The offering included Series A and Series B warrants to purchase an aggregate of 3,567,164 shares at an exercise price of $1.09.
- A $1,400,000 bridge promissory note from January 15, 2026, was automatically converted into this PIPE offering.
- The company received only $850,000 in new cash proceeds from the closing.
- Vivos is required to file a resale registration statement within 45 days of closing.
- The company paid $50,000 of the investor's legal fees.